ReviewClinical, cosmetic and investigational dermatology2026
Acral Vitiligo: A Comprehensive Review of Clinical Features, Pathogenesis, and Novel Therapeutic Advances.
Review in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acral vitiligo, a distinct subtype predominantly affecting the distal extremities (hands and feet), presents significant clinical challenges due to its treatment resistance and profound psychosocial impact. This narrative review systematically synthesizes current knowledge on the epidemiology, unique clinical presentations, and the specific pathophysiological mechanisms underlying this recalcitrant variant. We critically appraise recent advances in diagnosis and treatment, integrating findings from clinical studies, experimental researches, and case reports. The central aim is to provide a nuanced, evidence-based understanding of acral vitiligo to guide clinical management. We critically evaluate contemporary treatment modalities, including the emerging roles of Janus kinase (JAK) inhibitors and biologic agents, while also addressing the crucial dimension of psychosocial burden. Finally, we delineate key knowledge gaps-particularly the lack of acral‑specific outcome measures and head‑to‑head comparative trials-and propose future research directions to improve outcomes for patients with this therapeutically orphaned subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.